Global Custom Market Research Reports Provider Company

phone

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H1 2018

  • Published Date: 27 Feb 2018
  • Number of Pages: 55
  • Category: Pharmaceuticals
  • Country: Global

20%

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H1 2018

Summary

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Colorectal Cancer, Melanoma, Breast Cancer, Liver Cancer, Metastatic Melanoma, Pancreatic Cancer, Bladder Cancer, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Low-Grade Glioma, Lung Adenocarcinoma, Lung Cancer, Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease) and Sarcomas.

The latest report RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H1 2018, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeRAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H1 2018

Summary

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Colorectal Cancer, Melanoma, Breast Cancer, Liver Cancer, Metastatic Melanoma, Pancreatic Cancer, Bladder Cancer, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Low-Grade Glioma, Lung Adenocarcinoma, Lung Cancer, Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease) and Sarcomas.

The latest report RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H1 2018, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  

Publisher Name : Global Markets Direct


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
CBT Pharmaceuticals Inc
Chugai Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Millennium Pharmaceuticals Inc
Novartis AG
Redx Pharma Plc
VG Life Sciences Inc
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
(MG-005 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAL-3833 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBT-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBCI-0902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FYA-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-95573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxychloroquine + sorafenib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LXH-254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-05358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit RAF1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor
Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-cancer drug HM95573 at ASCO
Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting
Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting
Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent
Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment
Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study
Mar 14, 2014: VG Life Sciencess Reports on Clinical Outcomes in Phase I Cancer Study
Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study
Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;
Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study
Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine
Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib
Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerTable of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
CBT Pharmaceuticals Inc
Chugai Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Millennium Pharmaceuticals Inc
Novartis AG
Redx Pharma Plc
VG Life Sciences Inc
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
(MG-005 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAL-3833 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBT-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBCI-0902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FYA-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-95573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxychloroquine + sorafenib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LXH-254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-05358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit RAF1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor
Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-cancer drug HM95573 at ASCO
Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting
Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting
Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent
Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment
Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study
Mar 14, 2014: VG Life Sciencess Reports on Clinical Outcomes in Phase I Cancer Study
Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study
Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;
Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study
Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine
Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib
Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
  



List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Basilea Pharmaceutica Ltd, H1 2018
Pipeline by CBT Pharmaceuticals Inc, H1 2018
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Redx Pharma Plc, H1 2018
Pipeline by VG Life Sciences Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Basilea Pharmaceutica Ltd, H1 2018
Pipeline by CBT Pharmaceuticals Inc, H1 2018
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Redx Pharma Plc, H1 2018
Pipeline by VG Life Sciences Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
  



List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administrations, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administrations, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  



REASONS FOR DOING THE STUDY Ultrafast lasers emit ultrashort pulses having duration of picoseconds to femtoseconds. Ultrafast laser properties such as short duration, broad spectral bandwidth and short coherence length support the

View Report

Success Case Study: Suntory Craft Boss - Craft-style ready-to-drink coffee resonates with Japans Millennials Success Case Study: Suntory Craft Boss , is part of GlobalDatas Successes and Failures research. It examines the

View Report

The Global Military Aircraft Engines Market 2018-2028 The Global Military Aircraft Engines Market 2018-2028, report offers a detailed analysis of the industry, with market size forecasts covering the next ten years.

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports